Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Company Overview

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Key Stats

• Today's Range: $3.63 to $3.63
• 50-Day Range: $2.88 to $3.61
• 52-Week Range: $2.70 to $4.72
• Volume: 1,557 shs
• Average Volume: 943,580 shs
• Market Capitalization: $687.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Arbutus Biopharma Stock Analysis - MarketRank™

Arbutus Biopharma scored higher than 44% of companies evaluated by MarketBeat, and ranked 760th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arbutus Biopharma is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arbutus Biopharma is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arbutus Biopharma has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.07% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arbutus Biopharma does not currently pay a dividend.

Dividend Growth

Arbutus Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.07% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Arbutus Biopharma has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.35

News Sentiment

Arbutus Biopharma has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Arbutus Biopharma this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

5 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABUS Stock Analysis - Frequently Asked Questions

How have ABUS shares performed this year?

Arbutus Biopharma's stock was trading at $3.27 at the beginning of the year. Since then, ABUS shares have increased by 9.9% and is now trading at $3.5930.
View the best growth stocks for 2025 here.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Thursday, March, 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The biopharmaceutical company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative trailing twelve-month return on equity of 68.18%.

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's top institutional shareholders include Bank of New York Mellon Corp (0.18%), Rhumbline Advisers (0.10%), SBI Securities Co. Ltd. (0.04%) and Teacher Retirement System of Texas (0.02%).
View institutional ownership trends.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 5/01/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABUS
• CIK: 1447028
• Web: www.arbutusbio.com
• Phone: (267) 469-0914
• Fax: 604-419-3201
• Employees: 90
• Year Founded: 1992

Price Target and Rating

• Average Stock Price Target: $5.50
• High Stock Price Target: $7.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +52.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-72,850,000.00
• Net Margins: -1,137.65%
• Pretax Margin: -1,137.65%
• Return on Equity: -68.18%
• Return on Assets: -51.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.02
• Quick Ratio: 7.02

Sales & Book Value

• Annual Sales: $6.17 million
• Price / Sales: 112.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.63 per share
• Price / Book: 5.73

Miscellaneous

• Outstanding Shares: 191,480,000
• Free Float: 181,912,000
• Market Cap: $691.24 million
• Optionable: Optionable
• Beta: 1.45